Search results for: Motoko Tachihara

Items from 1 to 13 out of 13 results

article

A randomized phase 3 study of maintenance therapy with S‐1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S‐1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L)

Kaoru Tanaka, Satoshi Morita, Masahiko Ando, Takuma Yokoyama, more

Cancer > 126 > 16 > 3648 - 3656

Background A randomized phase 3 study was performed to investigate the efficacy and safety of maintenance therapy with S‐1 after induction therapy with carboplatin plus S‐1 in patients with advanced squamous non–small cell lung cancer (NSCLC). Methods Chemotherapy‐naive patients with advanced or relapsed squamous NSCLC were treated with carboplatin (area under the curve of 5 on day 1 every 3 weeks)...

article

Overexpression of CD 133 and BCL‐2 in non‐small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement‐positive adenocarcinoma

Kiyoko Koyama, Naoko Katsurada, Naoe Jimbo, Motoko Tachihara, more

Pathology International > 69 > 5 > 294 - 299

Transformation to small cell lung cancer is one phenomenon of acquired resistance to anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in ALK rearrangement‐positive non‐small cell lung cancer (NSCLC). Few case reports have focused on other types of histological transformation. We report a case of transformation of ALK rearrangement‐positive adenocarcinoma to NSCLC with neuroendocrine differentiation...

article

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

Motoko Tachihara, Shunichi Negoro, Takako Inoue, Motohiro Tamiya, more

BMC Cancer > 2018 > 18 > 1 > 1-6

Background Immune checkpoint inhibitors (ICIs) have emerged as promising therapeutic agents in non-small cell lung cancer (NSCLC). However, the duration for which ICIs should be continued remains a clinical problem. Methods We examined the efficacy of anti-PD-1/PD-L1 inhibitors after the discontinuation of antibodies due to adverse events (AEs) in patients with NSCLC. This was a multicenter retrospective...

article

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

Toshiaki Takahashi, Takeharu Yamanaka, Takashi Seto, Hideyuki Harada, more

The Lancet Oncology > 2017 > 18 > 5 > 663-671

Results from a previous phase 3 study suggested that prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases and prolongs overall survival compared with no prophylactic cranial irradiation in patients with extensive-disease small-cell lung cancer. However, because of the absence of brain imaging before enrolment and variations in chemotherapeutic regimens and irradiation...

article

Utility of cell blocks obtained by catheter aspiration via a guide sheath during endobronchial ultrasonography

Nobuko Hazeki, Motoko Tachihara, Ryuko Tsukamoto, Shuntaro Tokunaga, more

Respiratory Investigation > 2017 > 55 > 2 > 161-165

The demand for adequate tissue samples for both morphological assessment and molecular studies on lung cancer treatment has increased. The aim of this study was to evaluate whether cell blocks (CBs) prepared from endobronchial ultrasonography with guide sheath (EBUS-GS) rinsing following catheter aspiration provide additional information.We produced CBs from rinse fluid obtained from washing the inside...

article

Administration of JTE013 abrogates experimental asthma by regulating proinflammatory cytokine production from bronchial epithelial cells

Tomomi Terashita, Kazuyuki Kobayashi, Tatsuya Nagano, Yoshitaka Kawa, more

Respiratory Research > 2016 > 17 > 1 > 1-8

Background Sphingosine-1-phosphate (S1P) is a bioactive phospholipid that acts as a signal transducer by binding to S1P receptors (S1PR) 1 to 5. The S1P/S1PRs pathway has been associated with remodeling and allergic inflammation in asthma, but the expression pattern of S1PR and its effects on non-immune cells have not been completely clarified. The aim of this study was to examine the contribution...

article

Diagnostic utility of additional conventional techniques after endobronchial ultrasonography guidance during transbronchial biopsy

Kei Kunimasa, Motoko Tachihara, Daisuke Tamura, Shuntaro Tokunaga, more

Respirology > 21 > 6 > 1100 - 1105

Background and objective Endobronchial ultrasonography with a guide sheath transbronchial biopsy (EBUS‐GS TBB) has been used to diagnose peripheral pulmonary lesions (PPLs). In this study, we evaluated the diagnostic utility of conventional TBB after EBUS‐GS TBB. Methods A retrospective analysis of patients who underwent conventional TBB after EBUS‐GS TBB for PPL between August 1, 2012 and December...

article

Cholesteryl palmitate crystals in bronchoalveolar lavage fluid smears as a possible prognostic biomarker for chronic interstitial pneumonia: A preliminary study

Naoko Fukuhara, Motoko Tachihara, Yoshinori Tanino, Junpei Saito, more

Respiratory Investigation > 2016 > 54 > 2 > 109-115

We observed cholesterol-like crystals (Crystal X) in the bronchoalveolar lavage fluid (BALF) smears of patients with diffuse pulmonary disease. We analyzed the clinical data of patients with and without crystals, and elucidated the structure of Crystal X and its concentration in the BALF.Two hundred eighty-nine patients with diffuse pulmonary disease who underwent bronchoalveolar lavage (BAL) were...

article

A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110)

Kazumi Nishino, Fumio Imamura, Toru Kumagai, Nobuyuki Katakami, more

Lung Cancer > 2015 > 89 > 2 > 146-153

This randomized phase II trial investigated the efficacy and safety of docetaxel plus bevacizumab and S-1 plus bevacizumab in the second-line treatment of non-squamous (non-Sq) non-small-cell lung cancer (NSCLC).Patients with non-Sq NSCLC who experienced disease progression after prior platinum-based chemotherapy with or without bevacizumab were randomly assigned to receive docetaxel plus bevacizumab...

article

A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)

Yoshihiro Hattori, Miyako Satouchi, Temiko Shimada, Yoshiko Urata, more

Lung Cancer > 2015 > 87 > 2 > 136-140

We have conducted a phase 2 study to evaluate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab in patients with non-squamous non-small-cell lung cancer (NSCLC) who are epidermal growth factor receptor (EGFR) mutation positive and for whom EGFR-tyrosine kinase inhibitor (TKI) 1st-line has failed.Patients with stage IIIB or IV non-squamous NSCLC harbored activating EGFR mutations...

article

Synergistic effects of pemetrexed and amrubicin in non-small cell lung cancer cell lines: Potential for combination therapy

Yukihisa Hatakeyama, Kazuyuki Kobayashi, Tatsuya Nagano, Daisuke Tamura, more

Cancer Letters > 2014 > 343 > 1 > 74-79

The purpose is to examine the synergistic effect of pemetrexed (PEM) and amrubicin (AMR) on the proliferation of lung cancer cell lines. In vitro, dose-dependent synergistic effects of concurrent PEM and AMRol, which is an active metabolite of AMR were observed in A549 and H460 cells. In real-time RT-qPCR analysis and western blotting, expression of the target enzymes of PEM were suppressed in cells...

article

Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601

Shunichi Sugawara, Makoto Maemondo, Motoko Tachihara, Akira Inoue, more

Lung Cancer > 2013 > 81 > 1 > 91-96

The optimal chemotherapy with thoracic radiotherapy (TRT) for locally advanced non-small-cell lung cancer (NSCLC) remains to be established. This randomized phase II study of concurrent chemoradiotherapy was conducted to compare uracil/tegafur (UFT) and cisplatin with vinorelbine and cisplatin for stage III NSCLC.Patients with unresectable stage III NSCLC were randomized to receive UP (400mg/m ...

article

A virtual bronchoscopic navigation system under X-ray fluoroscopy for transbronchial diagnosis of small peripheral pulmonary lesions

Motoko Tachihara, Takashi Ishida, Kenya Kanazawa, Aya Sugawara, more

Lung Cancer > 2007 > 57 > 3 > 322-327

We had reported the utility of virtual bronchoscopic navigation system under CT-guidance for the diagnosis of small peripheral pulmonary lesions (PPLs). This study investigated the efficacy of virtual bronchoscopic navigation system for the diagnosis of small PPLs under X-ray fluoroscopy. We performed bronchoscopy with this system for 94 consecutive patients with 96 PPLs (≤30mm in longest diameter;...

Filter options

Publication date

Set your own date range

Keywords

BRONCHOSCOPY (3)
LUNG CANCER (3)
BEVACIZUMAB (2)
CARBOPLATIN (2)
NON-SMALL CELL LUNG CANCER (2)
NON-SMALL-CELL LUNG CANCER (2)
SECOND-LINE (2)
ADENOCARCINOMA (1)
ADVERSE EVENT (1)
ALK REARRANGEMENT‐POSITIVE LUNG CANCER (1)
AMRUBICIN (1)
ANTI-PD-1/L1 INHIBITOR (1)
ASPIRATION METHOD (1)
BEAS-2B (1)
BRONCHOALVEOLAR LAVAGE (1)
CANCER STEM CELL (1)
CCL3 (1)
CELL BLOCK (1)
CHEMORADIOTHERAPY (1)
CHOLESTERYL PALMITATE (1)
CISPLATIN (1)
CRYSTAL (1)
DISCONTINUATION (1)
DOCETAXEL (1)
ENDOBRONCHIAL ULTRASONOGRAPHY WITH A GUIDE SHEATH (1)
ENDOSONOGRAPHY (1)
EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION (1)
EPITHELIAL CELLS (1)
IMAGE‐GUIDED BIOPSY (1)
INTERSTITIAL PNEUMONIA (1)
JTE013 (1)
LOCALLY ADVANCED (1)
MAINTENANCE THERAPY (1)
NAVIGATION (1)
NEUROENDOCRINE CARCINOMA (1)
NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (1)
NON–SMALL CELL LUNG CANCER (NSCLC) (1)
PACLITAXEL (1)
PEMETREXED (1)
PHASE II (1)
PULMONARY NODULES (1)
RANDOMIZED PHASE II TRIAL (1)
S-1 (1)
SMALL CELL LUNG CANCER (1)
SMALL PERIPHERAL PULMONARY LESION (1)
SPHINGOSINE-1-PHOSPHATE (1)
SQUAMOUS CELL CARCINOMA (1)
SURFACTANT (1)
S‐1 (1)
THYMIDYLATE SYNTHASE (1)
TRANSBRONCHIAL DIAGNOSIS (1)
TRANSFORMATION (1)
UFT (1)
ULTRATHIN BRONCHOSCOPE (1)
VINORELBINE (1)
VIRTUAL BRONCHOSCOPY (1)
more

Data set

Elsevier (8)
Wiley (3)
Springer (2)

INFONA - science communication portal

Search results for: Motoko Tachihara

A randomized phase 3 study of maintenance therapy with S‐1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S‐1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L)

Overexpression of CD 133 and BCL‐2 in non‐small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement‐positive adenocarcinoma

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

Utility of cell blocks obtained by catheter aspiration via a guide sheath during endobronchial ultrasonography

Administration of JTE013 abrogates experimental asthma by regulating proinflammatory cytokine production from bronchial epithelial cells

Diagnostic utility of additional conventional techniques after endobronchial ultrasonography guidance during transbronchial biopsy

Cholesteryl palmitate crystals in bronchoalveolar lavage fluid smears as a possible prognostic biomarker for chronic interstitial pneumonia: A preliminary study

A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110)

A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)

Synergistic effects of pemetrexed and amrubicin in non-small cell lung cancer cell lines: Potential for combination therapy

Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601

A virtual bronchoscopic navigation system under X-ray fluoroscopy for transbronchial diagnosis of small peripheral pulmonary lesions

Filter options

Publication date

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: Motoko Tachihara

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options